Zai Lab (ZLAB) and Novocure (NVCR) have reported that the Phase 3 PANOVA-3 trial successfully achieved its primary goal by demonstrating a statistically significant improvement in median overall survival compared to the control group. This trial evaluated the efficacy of Tumor Treating Fields (TTFields) therapy in combination with gemcitabine and nab-paclitaxel as a first-line treatment option for patients with unresectable, locally advanced pancreatic adenocarcinoma.
Novocure intends to pursue regulatory approval for TTFields in this particular condition, leveraging the positive results from PANOVA-3. Similarly, Zai Lab is set to seek regulatory approval in China for this therapeutic approach.
